TY - JOUR
T1 - STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
T2 - A SYSTEMATIC REVIEW AND META-ANALYSIS
AU - Fang, Hwa Shin
AU - Bai, Chyi Huey
AU - Cheng, Cheng Kuo
N1 - Publisher Copyright:
Copyright © by Ophthalmic Communications Society, Inc.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose:To compare the visual and anatomical outcomes between strict pro re nata (strict PRN) and treat-and-extend (T&E) anti-vascular endothelial growth factor (anti-VEGF) regimens for neovascular age-related macular degeneration (nAMD).Methods:A meta-analysis of 1-year and 2-year changes between strict PRN and T&E anti-VEGF regimens were conducted in both randomized controlled trials (RCTs) and real-world studies (RWSs). The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and weighted mean numbers of visits and injections were evaluated.Results:A total of 19 RCTs and 23 RWSs (2,530 eyes in strict PRN and 4,399 eyes in T&E) were included. Mean BCVA change in strict PRN group in both 1-year and 2-year (5.95 and 5.78, respectively) was noninferior to the T&E group (7.85 and 5.96, respectively). Mean CRT changes were also similar in both strict PRN and T&E groups. Mean number of visits were significantly more in the strict PRN group, whereas mean number of injections was significantly more in the T&E group.Conclusion:The strict PRN regimen demonstrates a noninferior BCVA improvement to the T&E regimen, achieving fewer injections, and may be both economically and medically beneficial. Both selections should be provided to patients with an overall consideration.
AB - Purpose:To compare the visual and anatomical outcomes between strict pro re nata (strict PRN) and treat-and-extend (T&E) anti-vascular endothelial growth factor (anti-VEGF) regimens for neovascular age-related macular degeneration (nAMD).Methods:A meta-analysis of 1-year and 2-year changes between strict PRN and T&E anti-VEGF regimens were conducted in both randomized controlled trials (RCTs) and real-world studies (RWSs). The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and weighted mean numbers of visits and injections were evaluated.Results:A total of 19 RCTs and 23 RWSs (2,530 eyes in strict PRN and 4,399 eyes in T&E) were included. Mean BCVA change in strict PRN group in both 1-year and 2-year (5.95 and 5.78, respectively) was noninferior to the T&E group (7.85 and 5.96, respectively). Mean CRT changes were also similar in both strict PRN and T&E groups. Mean number of visits were significantly more in the strict PRN group, whereas mean number of injections was significantly more in the T&E group.Conclusion:The strict PRN regimen demonstrates a noninferior BCVA improvement to the T&E regimen, achieving fewer injections, and may be both economically and medically beneficial. Both selections should be provided to patients with an overall consideration.
KW - aflibercept
KW - age-related macular degeneration
KW - bevacizumab
KW - meta-analysis
KW - pro re nata (PRN)
KW - ranibizumab
KW - treat-and-extend (T&E)
KW - vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=85148678719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148678719&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000003690
DO - 10.1097/IAE.0000000000003690
M3 - Article
C2 - 36669130
AN - SCOPUS:85148678719
SN - 0275-004X
VL - 43
SP - 420
EP - 432
JO - Retina
JF - Retina
IS - 3
ER -